UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 109

Sortiert nach

Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy

Annals of oncology, 2019-02, Vol.30 (2), p.236-242

2019

Link zum Volltext

Verfügbarkeit prüfen

Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system

International journal of cancer, 2012-04, Vol.130 (7), p.1590-1597

2012

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy

Annals of oncology, 2012-05, Vol.23 (5), p.1144-1150

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib/IIa study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated P68, which prevents nuclear β-catenin translocation in patients with triple negative breast cancer

Annals of oncology, 2018-10, Vol.29, p.viii119-viii119

2018

Link zum Volltext

Verfügbarkeit prüfen

Elevated 70kDa heat shock protein (hsp70) and autophagy levels in peripheral blood mononuclear cells (PBMCs) in women with a malignant breast mass

Annals of oncology, 2018-10, Vol.29, p.viii47-viii47

2018

Link zum Volltext

Verfügbarkeit prüfen

Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial

Clinical & translational oncology, 2018-11, Vol.20 (11), p.1474-1483

2018

Link zum Volltext

Verfügbarkeit prüfen

Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer

Annals of oncology, 2007-04, Vol.18 (4), p.716-721

2007

Link zum Volltext

Verfügbarkeit prüfen

Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?

Annals of oncology, 2011-11, Vol.22 (11), p.2387-2393

2011

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients

British journal of cancer, 2009-12, Vol.101 (11), p.1813-1816

2009

Link zum Volltext

Verfügbarkeit prüfen

Incidence of and survival following brain metastases among women with inflammatory breast cancer

Annals of oncology, 2010-12, Vol.21 (12), p.2348-2355

2010

Link zum Volltext

Verfügbarkeit prüfen

An overview of the status of imaging screening technology for breast cancer

Annals of oncology, 2004-01, Vol.15 (suppl-1), p.i18-i26

2004

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumor cells in metastatic inflammatory breast cancer

Annals of oncology, 2009-11, Vol.20 (11), p.1824-1828

2009

Link zum Volltext

Verfügbarkeit prüfen

The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma

Annals of oncology, 2004-09, Vol.15 (9), p.1406-1412

2004

Link zum Volltext

Verfügbarkeit prüfen

Expert Discussion: HER2-Positive Breast Cancer

Breast care (Basel, Switzerland), 2021-08, Vol.16 (4), p.422-428

2021

Link zum Volltext

Verfügbarkeit prüfen

414 Clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: Interim report from the phase 1 clinical trial

European journal of cancer supplements, 2010-11, Vol.8 (7), p.131-132

2010

Link zum Volltext

Verfügbarkeit prüfen

Treatment of Uterine Sarcoma at the Royal Marsden Hospital from 1974 to 1998

Clinical oncology (Royal College of Radiologists (Great Britain)), 2004-06, Vol.16 (4), p.261-268

2004

Link zum Volltext

Verfügbarkeit prüfen

Mucinous Cancer of the Appendix: Challenges in Diagnosis and Treatment

Journal of chemotherapy (Florence), 2007-08, Vol.19 (4), p.451-454

2007

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-10-10: Tumor infiltrating lymphocytes (TILS) among high risk for recurrence breast cancer patients treated with tetrathimolybdate (TM)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-10-10

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD9-07: A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with high risk breast cancer (BC): Role of collagen processing and tumor microenvironment

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD9-07-PD9-07

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-12-08: Phase I study of low dose oral cyclophosphamide (C) plus the poly-ADP-ribose- polymerase (PARP) inhibitor veliparib (V) in women with HER2/neu-negative inoperable locally advanced/metastatic breast cancer (MBC): NCI P8853

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-12-08

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-10-02: A phase II study of copper-depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence: Updated results

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-10-02

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-07-52: Identification of serum biomarkers associated with Akt inhibitor MK-2206-induced toxicity in a pre-surgical breast cancer (BC) trial

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-52

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-02-02: Targeting the tumor microenvironment: A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-02-02

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-01-19: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-19-OT2-01-19

2017

Link zum Volltext

Verfügbarkeit prüfen

Favorable Outcome of Ovarian Germ Cell Malignancies Treated with Cisplatin or Carboplatin-Based Chemotherapy: A Hellenic Cooperative Oncology Group Study

Gynecologic oncology, 1998-07, Vol.70 (1), p.70-74

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(100)

Publikationsform

Artikel
(107)
Tagungsberichte
(2)

Sprache

Englisch
(109)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy

Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy

Phase Ib/IIa study of RX-5902, a novel orally bioavailable inhibitor of phosphorylated P68, which prevents nuclear β-catenin translocation in patients with triple negative breast cancer

Elevated 70kDa heat shock protein (hsp70) and autophagy levels in peripheral blood mononuclear cells (PBMCs) in women with a malignant breast mass

Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial

Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer

Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?

Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients

Incidence of and survival following brain metastases among women with inflammatory breast cancer

An overview of the status of imaging screening technology for breast cancer

Circulating tumor cells in metastatic inflammatory breast cancer

The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma

Expert Discussion: HER2-Positive Breast Cancer

414 Clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: Interim report from the phase 1 clinical trial

Treatment of Uterine Sarcoma at the Royal Marsden Hospital from 1974 to 1998

Mucinous Cancer of the Appendix: Challenges in Diagnosis and Treatment

Abstract P1-10-10: Tumor infiltrating lymphocytes (TILS) among high risk for recurrence breast cancer patients treated with tetrathimolybdate (TM)

Abstract PD9-07: A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with high risk breast cancer (BC): Role of collagen processing and tumor microenvironment

Abstract P6-12-08: Phase I study of low dose oral cyclophosphamide (C) plus the poly-ADP-ribose- polymerase (PARP) inhibitor veliparib (V) in women with HER2/neu-negative inoperable locally advanced/metastatic breast cancer (MBC): NCI P8853

Abstract P1-10-02: A phase II study of copper-depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence: Updated results

Abstract P3-07-52: Identification of serum biomarkers associated with Akt inhibitor MK-2206-induced toxicity in a pre-surgical breast cancer (BC) trial

Abstract P3-02-02: Targeting the tumor microenvironment: A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence

Abstract OT2-01-19: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer

Favorable Outcome of Ovarian Germ Cell Malignancies Treated with Cisplatin or Carboplatin-Based Chemotherapy: A Hellenic Cooperative Oncology Group Study

Suchergebnisse filtern